Lefamulin acetate (Xenleta)

Catalog No.S3496 Synonyms: BC-3781 acetate

For research use only.

Lefamulin acetate (Xenleta, BC-3781 acetate) is a pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP) treatment. Lefamulin acetate inhibits protein synthesis by binding to the peptidyl transferase center of the 50S bacterial ribosome, thus preventing the binding of transfer RNA for peptide transfer.

Lefamulin acetate (Xenleta) Chemical Structure

CAS No. 1350636-82-6

Selleck's Lefamulin acetate (Xenleta) has been cited by 1 Publication

Purity & Quality Control

Choose Selective Bacterial Inhibitors

Biological Activity

Description Lefamulin acetate (Xenleta, BC-3781 acetate) is a pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP) treatment. Lefamulin acetate inhibits protein synthesis by binding to the peptidyl transferase center of the 50S bacterial ribosome, thus preventing the binding of transfer RNA for peptide transfer.

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 567.78
Formula

C30H49NO7S

CAS No. 1350636-82-6
Storage 3 years -20°C powder
2 years -80°C in solvent

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05111002 Recruiting Drug: Lefamulin|Drug: Doxycycline Mycoplasma Genitalium Infection University of Washington|Nabriva Therapeutics AG April 22 2022 Phase 1|Phase 2
NCT05225805 Recruiting Drug: Lefamulin Cystic Fibrosis Nabriva Therapeutics AG March 1 2022 Phase 1
NCT03131141 Completed Drug: BC-3781 Healthy Nabriva Therapeutics AG|Quotient Clinical January 8 2017 Phase 1
NCT02557789 Completed Drug: Lefamulin Healthy Nabriva Therapeutics AG June 2015 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Lefamulin acetate (Xenleta) | Lefamulin acetate (Xenleta) supplier | purchase Lefamulin acetate (Xenleta) | Lefamulin acetate (Xenleta) cost | Lefamulin acetate (Xenleta) manufacturer | order Lefamulin acetate (Xenleta) | Lefamulin acetate (Xenleta) distributor